{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '43', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'frequently reported Grade 3 or 4 AEs were neutropenia, leukopenia, hypertension,', 'thrombocytopenia, and febrile neutropenia. No AEs resulting in death were reported [Nishio,', 'M., et al 2013].', 'The present study is designed to further evaluate the safety and efficacy of combination', 'therapy of lenvatinib and pembrolizumab in adult participants with treatment-na\u00efve,', 'metastatic NSCLC with a TPS 1%. The outcomes for participants evaluated in this study', 'would be further improved if the safety profile of a pembrolizumab plus lenvatinib', 'combination remains acceptable and is shown to improve outcomes compared with', 'pembrolizumab monotherapy; thus, this study could support the regulatory approval of this', 'combination in this patient population.', '2.2', 'Background', 'Pembrolizumab is a potent humanized IgG4 mAb with high specificity of binding to the', 'PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2. Based on preclinical in', 'vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD-1.', 'Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as', 'an IV immunotherapy for advanced malignancies. Keytruda\u00ae (pembrolizumab) is indicated', 'for the treatment of patients across a number of indications. For more details on specific', \"indications, refer to the pembrolizumab Investigator's Brochure (IB).\", 'Lenvatinib (also known as E7080 or MK-7902) inhibits the kinase activities of vascular', 'endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and', 'VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic', 'angiogenesis, tumor growth, and cancer progression in addition to their normal cellular', 'functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-', 'derived growth factor receptor alpha (PDGFRa), KIT, and RET. Lenvatinib also exhibited', 'antiproliferative activity in cell lines dependent on activated FGFR signaling with a', 'concurrent inhibition of FGF-receptor substrate 2a phosphorylation. Once daily (QD) dosing', 'of lenvatinib combined with pembrolizumab is currently being developed for the treatment of', 'metastatic NSCLC. Refer to the respective IBs/approved labeling for detailed background', 'information on pembrolizumab and lenvatinib.', '2.2.1', 'Pharmaceutical and Therapeutic Background', '2.2.1.1', 'Lenvatinib', 'Angiogenesis, the formation of new blood vessels from a pre-existing vascular network, is', 'essential for tumor growth and metastasis. VEGF and its family of receptors (VEGFRs 1-3)', 'play a major role in tumor angiogenesis [Ferrara, N., et al 2003] [Ellis, L. M. 2008]', '[Tammela, T. 2010]. Accumulated evidence suggests that FGF and its receptor tyrosine', 'kinase, FGFR, also play important roles in tumor angiogenesis [Cross, M. J. 2001] [Lieu, C.,', 'et al 2011] (Limaverde-Sousa, G., et al 2014].', 'Lenvatinib is a potent multiple RTKi that selectively inhibits VEGF receptors, VEGFR1', '(FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), FGFR1-4 PDGFRa, c-kit, and RET. Among', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '44', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'known kinase inhibitors in clinical use, lenvatinib is one of the only inhibitors currently', 'labeled with a mechanism of action as an inhibitor of not only VEGFRs but also FGFRs,', 'both of which are currently believed to be very important for tumor angiogenesis.', 'Lenvatinib inhibited cell free kinase activities for VEGFR1-3 and FGFR1-3 with Ki values', 'around 1 nmol/L, and 8-22 nmol/L, respectively. In cell-based assays, lenvatinib inhibited', 'VEGF-derived and FGF-derived tube formation of HUVEC with IC50 values of 2.1 and 7.3', 'nmol/L, respectively. Analysis of the signal transduction molecules revealed that lenvatinib', 'inhibited both the MAPK pathway and the mTOR-S6K-S6 pathway in HUVECs triggered by', 'activated VEGFR and FGFR. Furthermore, lenvatinib (10, 30 mg/kg) significantly inhibited', 'both VEGF- and FGF-driven angiogenesis in a murine in vivo model [Yamamoto, Y., et al', '2014]. In vivo, lenvatinib exhibited antitumor activity against various human tumor', 'xenografts in athymic mice including 5 types of thyroid carcinomas (differentiated [papillary', 'and follicular], anaplastic, squamous, and medullary thyroid carcinomas), RCC, HCC,', \"melanoma, gastric cancer, NSCLC, ovarian cancer, Ewing's sarcoma, and osteosarcoma. In\", 'addition, the antitumor activity of lenvatinib in combination with other anticancer agents in', 'several xenograft models was greater than that of lenvatinib or the other agents alone.', 'In summary, lenvatinib inhibited VEGF-driven VEGFR2 phosphorylation and suppressed', 'proliferation and tube formation in human umbilical vein endothelial cell (HUVEC) models.', 'Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals.', 'These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of', 'angiogenesis and may be useful as either monotherapy or in combination with other', 'anticancer drugs.', '2.2.1.2', 'Pembrolizumab', 'Keytruda\u00ae (pembrolizumab) is indicated for the treatment of patients across a number of', 'indications. For more details on specific indications, refer to the pembrolizumab IB.', '2.2.1.3', 'Pembrolizumab With Lenvatinib', 'The importance of intact immune surveillance function in controlling outgrowth of neoplastic', 'transformations has been known for decades [Disis, M. L. 2010]. Accumulating evidence', 'shows a correlation between tumor-infiltrating lymphocytes in cancer tissue and favorable', 'prognosis in various malignancies. In particular, the presence of CD8+ T-cells and the ratio', 'of CD8+ effector T-cells/FoxP3+ regulatory T-cells (T-regs) correlates with improved', 'prognosis and long-term survival in solid malignancies, such as ovarian, colorectal, and', 'pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and renal cell carcinoma.', 'Tumor-infiltrating lymphocytes can be expanded ex vivo and reinfused, inducing durable', 'objective tumor responses in cancers such as melanoma [Dudley, M. E., et al 2005] [Hunder,', 'N. N., et al 2008]. In preclinical models, lenvatinib decreased the tumor-associated', 'macrophage (TAM) population, which is known as an immune-regulator in the tumor', 'microenvironment. The decrease in TAM population was accompanied by increases in', 'activated cytotoxic T-cell populations through stimulation of interferon-gamma signaling,', 'resulting in increased immune activation [Kimura, T., et al 2018]. The immune-modulating', 'effect of lenvatinib may result in a potent combination effect with PD-1/L1 signal inhibitors.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']\n\n###\n\n", "completion": "END"}